Research P atients with type 2 diabetes mellitus and hypertension are at increased risk of cardiovascular events and chronic renal failure requiring dialysis.
In 1998 the Diabetes Risk Evaluation and Microalbuminuria (DREAM 1) study was initiated at the request of the Battlefords Tribal Council Indian Health Services to assess the prevalence of risk factors for end-stage renal disease (ESRD) among First Nations people with type 2 diabetes in the Battlefords region of northern Saskatchewan. 6 In 2000 the DREAM 2 pilot study demonstrated a reduction of systolic blood pressure when home care nurses measured blood pressure at regular intervals and notified the patient's family physician. 6 In this article, we report the findings of the DREAM 3 study, which was designed to evaluate the effect on blood pressure control of an algorithm of pharmacologic therapy implemented by home care nurses in a community setting.
with the Battlefords Tribal Council Indian Health Services through community screening clinics and during visits by home care nurses and home health aides between September 2001 and March 2003. Inclusion and exclusion criteria are found in Box 1. All patients provided written informed consent, and an interpreter was available at all stages of the study. The protocol was in accordance with the Declaration of Helsinki and was approved by the ethics committees of the Sunnybrook and Women's College Health Sciences Centre, the University of Toronto and the University of Saskatchewan.
All participants were seen by a home care nurse in the medical clinic on their reserve at baseline, at 6 weeks and at 3, 6, 9 and 12 months after enrolment. They were all seen by a hypertension specialist (S.W.T. or G.P.) at their baseline and final visits. Participants were accompanied by a home health aide from their reserve, when possible, to help with language and cultural issues. All patients received healthy lifestyle classes, focusing on a healthier dietary regimen, exercise (30 minutes per day, 5 days per week), smoking cessation and drug adherence. 7 Participants were instructed to take their morning medications before each home care visit. Following each visit, a letter summarizing the patient's current medications, blood pressure and updated laboratory test results was completed and forwarded to the primary care physician. A summary of the clinical practice guidelines for managing hypertension in people with diabetes 8 was included with each letter. Also included were algorithms for glucose and lipid control (see online appendices, available at www.cmaj.ca/cgi /content/full/cmaj.050030/DC1); these algorithms were developed from current clinical practice guidelines.
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Randomization was performed by means of opaque sealed envelopes using a permuted block design, stratified by the 7 reserves. Envelopes were opened by the home care nurse in the presence of the physician and patient at the end of the baseline visit. Fifty subjects were randomly assigned to the treatment strategy and 49 to the control strategy.
Subjects assigned to the intervention group were asked to discontinue their antihypertensive medication at the baseline visit and to start taking the angiotensin II receptor blocker irbesartan at a dose of 150 mg/d. If on subsequent visits their blood pressure was not controlled, a stepped protocol approach to lower the blood pressure to the target (< 130/80 mm Hg) was begun, administered by the home care nurse under the indirect supervision of the hypertension specialist. The patient's drug regimen was titrated according to the hypertension management algorithm (Fig. 1) . All medications were offered by the First Nations Drug Benefits Plan. Local pharmacies were asked to provide medications in blister packs to aid adherence. After each medication change, follow-up was arranged with the patient's primary care physician. An accelerated titration schedule was allowed after consultation with the hypertension specialist for patients already taking 2 or more antihypertensive agents at baseline.
Participants assigned to the control group were assessed by the home care nurse on the same schedule as that set out for the intervention group. If their blood pressure was above the target on any study visit, follow-up was arranged with their primary care physician and a letter sent as described earlier.
In all cases, blood pressure was measured on each visit by the home care nurse using the BpTRU automated oscillometric blood pressure cuff (VSM Medtech Ltd., Vancouver).
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Blood pressure measurements were obtained at least half an hour after coffee or cigarettes, with the patient seated for 30 minutes; patients did not have to fast. In addition, a random urine sample was taken at baseline and every 3 months to determine the urine albumin:creatinine ratio; all blood and urine samples were sent to the laboratory in North Battleford. Microalbuminuria was defined as a urine albumin:creatinine ratio greater than 2.8 mg/mmol for women and greater than 2.0 mg/mmol for men.
12 Overt nephropathy was defined as a urine albumin:creatinine ratio greater than 28 mg/mmol for women and greater than 20 mg/mmol for men.
12 Renal function and serum potassium tests were repeated no more than 2 weeks after the baseline visit for patients in the treatment group because their drug therapy had been switched to a blocker of the renin-angiotensin aldosterone system. The primary outcome measure was the mean change in systolic blood pressure from baseline to the final visit in the intervention group compared with the control group. Sec- 
Exclusion criteria
• Use of β-blocker (subjects randomly assigned to the intervention group had their antihypertensive therapy switched at baseline, with no time to taper β-blocker therapy)
• Woman of child-bearing age not able to use a reliable method of birth control ondary outcome measures included the mean change in diastolic blood pressure over time in the 2 groups, the change in urine albumin status (normal to microalbuminuria to overt nephropathy or back) and the incidence of adverse events.
Estimates of sample size were based on an expected treatment effect of a drop in systolic blood pressure of 20 mm Hg in the intervention group (as found by Hoy and colleagues with a similar intervention
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) and a drop of 8 mm Hg in the control group (as found in the DREAM 2 study 6 ). A conservative common standard deviation of 25 mm Hg for systolic blood pressure was based on the results of the DREAM 2 study with a conservative correlation of 0.43 between systolic blood pressure readings taken 1 year apart. With α set at 0.05, we estimated that 60 subjects per group would provide a repeated-measures of analysis of variance (RANOVA) with 80% power to detect a significant difference in blood pressure between the 2 groups over time.
14 The change in blood pressure was determined by a comparison of readings taken at the baseline visit with those taken at the final visit.
Analyses were conducted on an intention-to-treat basis. Early in the study, 2 subjects withdrew before their second visit, specifying that they also withdrew their consent to allow their data to be used for analysis; therefore, these subjects were not included in the intention-to-treat analysis. Following this, subjects were notified during the consent process that their data would be used up to the point of withdrawing consent or to the end of the study. There were no crossovers from the intervention to the control strategy. We used the t test to compare baseline characteristics between groups and to compare measures from baseline to the final visit within groups; we used the χ 2 test to compare adequate blood pressure control between groups.
Results
First Nations people from the Battlefords region at increased risk of diabetes or with known diabetes were screened. A total of 179 were found to have either diabetes or, on further testing, a fasting blood glucose level in the diabetes range (Fig. 2 ). Of these, 61 had normal or controlled blood pressure (< 130/80 mm Hg), and the rest were invited to participate in the study. Seventeen people declined to participate for various reasons, including travel commitments and a fear of needles. Two other patients were excluded, one because of unstable retinopathy that required therapy and the other because she had become pregnant between the screening and baseline visits.
Data from the final 12-month visit, or from the last available visit for those lost to follow-up, were used in the intention-to-treat analysis. Four patients (2 from each group) were not included in the analysis: 2 (one from each group) were withdrawn from the study (one was found to have bilateral renal artery stenosis, an ex- clusion criteria, and was removed from the study for treatment; the other was enrolled into another study by the patient's family physician), and 2 (one from each group) withdrew their consent to allow use of their data for analysis. Three patients in the intervention group withdrew (one at 6 weeks and 2 at 9 months), and 5 in the control group withdrew (one after the baseline visit, one at 6 weeks, one at 3 months, one at 6 months and one at 9 months); their data were included in the intention-to-treat analysis. Therefore, 95 participants were included in the analysis: 48 in the intervention group and 47 in the control group. There were no significant differences between the 2 groups in demographic and clinical characteristics at baseline (Table 1) or at the final visit (data not shown).
In both the intervention and control groups, the change in blood pressure from baseline readings to those at the final visit was statistically significant ( Table 2 ). The reduction in systolic blood pressure was 7.0 mm Hg greater in the intervention group than in the control group, but this difference was not statistically significance (p = 0.14). The drop in diastolic blood pressure over time was 4.8 mm Hg greater in the intervention group than in the control group (p = 0.05); the RANOVA analysis was repeated 1000 times using bootstrap methods and yielded a median p value of 0.042. Overall, blood pressure targets (systolic < 130 mm Hg and diastolic < 80 mm Hg) were achieved in 48% of the participants with no significant difference between the 2 groups. Most of the patients in the control group had the doses of their hypertension medications titrated upward during the study by their primary care physicians.
The urine albumin level decreased from baseline to the final visit in both groups, from 157.8 to 115.5 mg/L in the treatment group and from 164.8 to 124.9 mg/L in the control group. The differences between and within the 2 groups were not statistically significant (Table 2) , even when log-transformed levels were analyzed (data not shown). Over the course of the study, the patients who had existing microalbuminuria did not have progression to overt nephropathy (Table 3 ). In many cases of existing overt nephropathy, the condition regressed to microalbuminuria during the study, although a regression to normal urine albumin levels did not occur (Table 3) .
Adverse events
The incidence of adverse events did not differ significantly between the 2 groups. Ten patients in the intervention group and 7 in the control group required admission to hospital. Of those in the intervention group, 2 were admitted because of myocardial infarction and angina, 1 patient was admitted on 6 occasions (once for management of diabetes and 5 times for treatment of skin infections and a lower-leg amputation), 2 were admitted because of pneumonia, 1 for management of diabetes, 1 because of bleeding hemorrhoids, 1 for treatment of depression, 1 because of a nonspecific allergic reaction (did not require a change in medications) and 1 because of pyelonephritis. In the control group, 2 of the 7 patients were admitted because of myocardial infarction and angina, 1 was admitted because of stroke. The other 4 patients were admitted for cholecystectomy, diabetes management, treatment of pneumonia (admitted twice) and management of resistant hypertension. All 17 patients were assessed at the 12-month visit and were included in the intention-to-treat analysis.
Interpretation
We found that, among First Nations people with existing hypertension and diabetes enrolled in the DREAM 3 study, the intervention of having a home care nurse monitor their blood pressure and follow a predefined treatment algorithm was as effective in lowering systolic blood pressure over time as was the control strategy of having a home care nurse monitor their blood pressure and their family physician decide on follow-up treatment. The intervention was, however, significantly more effective than the control strategy in lowering diastolic pressure. Improvement in blood pressure in both groups over the study period may have been due in part to the patients' involvement in the study program, with education given and blood pressure measured by the home care nurse in both groups. The urine albumin levels fell in both groups, but the difference between the groups was not significant.
Reducing blood pressure to the lower end of the renal autoregulatory range (< 130/80 mm Hg) has been found to result in significant renal protection. 15 Achieving this target in people with diabetes is currently suboptimal (about 9% in Canada). 16 High rates of control of multiple cardiovascular risk factors in the research setting have been achieved with a multidisciplinary approach. 17 Furthermore, blood pressure control has been found to be cost-effective. 18 The challenge lies in achieving effective blood pressure control in the community, as has been attempted in Australia. 19 Specially trained nurses instructed to follow detailed protocols and algorithms under the supervision of a specialist has been shown to improve diabetes outcomes, 20 as have nurse-led clinics. 21 A Canadian outreach program was effective in lowering blood pressure among people with diabetes living in a rural setting.
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New strategies and partnerships that include family physicians, nurses and specialists are required if cardiovascular risk factors such as hypertension are to be controlled.
Our study had several limitations. The home care nurse may have had an effect on blood pressure control independent of the treatment algorithm, which may explain the change in blood pressure seen in the control group. In addition, there may have been a halo effect because patients in the intervention group and the control group shared family physicians. By witnessing effects on blood pressure control, a patient in the intervention group may have influenced his or her family physician's practice for managing hypertension in a control patient. In planning the study, we recognized that these effects could challenge the potential superior benefit of the treatment protocol but, because the care received would have the potential to improve overall health care delivery for the subjects and their community, we felt it to be a fair trade-off. The study was unblinded because it was unacceptable to conceal treatment in this population. There were insufficient family physicians in the region to randomize by practice. Because the sample was smaller than 60 in each group, a significant difference in the primary outcome measure may have been missed owing to a type II error. Finally, in addition to the effect of the visits by the home care nurse and education in both groups, confounding from interactions between subjects within a single reserve or subjects sharing a family physician may have affected the outcome of this study and should be explored in future investigations.
The DREAM 3 study was designed to evaluate the effectiveness of an algorithm of pharmocologic therapy on blood pressure control implemented by a home care nurse in a community setting. High rates of blood pressure control in the community were achieved in both groups. New strategies such as that used in the DREAM 3 study and partnerships that involve family physicians, nurses and specialists are required if hypertension, a major reversible cardiovascular risk factor, is to be treated to target levels. Microalbuminuria is defined as urine albumin:creatinine ratio > 2.0 mg/mmol in women and > 2.8 mg/mmol in men. Overt nephropathy is defined as urine albumin:creatinine ratio > 28 mg/mmol in women and > 20 mg/mmol in men.
